Oorsprong van het eerstegraads netwerk van Jay Silber
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
Verity Pharmaceuticals, Inc.
 Verity Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Verity Pharmaceuticals, Inc. operates as a pharmaceutical company. It provides therapeutically relevant agents to the Canadian healthcare community. The company was founded in 2016 and is headquartered in Mississauga, ON.
4
| Private Company | Pharmaceuticals: Major | 4 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Jay Silber via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| STREET CAPITAL GROUP INC. | Finance/Rental/Leasing | Chief Executive Officer | |
| CORREVIO PHARMA CORP. | Pharmaceuticals: Major | Chief Executive Officer | |
University Health Network
 University Health Network Hospital/Nursing ManagementHealth Services University Health Network operates as a healthcare and medical research organization that provides patient care, education, and research services. Its programs include arthritis program, joint department of medical imaging, Krembil neuroscience center, laboratory medicine program, medical and community care, multi-organ transplant, Peter Munk cardiac center, Princess Margaret cancer, surgery and critical care program, and Toronto rehab. The company was founded in 1986 and is headquartered in Toronto, Canada. | Hospital/Nursing Management | Corporate Officer/Principal | |
Synergex Corp.
 Synergex Corp. Air Freight/CouriersTransportation Synergex Corp. provides supply chain management services in Latin America. It specializes in logistics services, distribution, licensing, sales, localization, packaging and marketing of digital entertainment products. The company was founded in 1986 and is headquartered in Mississauga, Canada. | Air Freight/Couriers | Director/Board Member | |
Magnum Uranium Corp.
 Magnum Uranium Corp. Other Metals/MineralsNon-Energy Minerals Magnum Uranium Corp. (MM:TSX.V) is a Canadian-based exploration company focused on the acquisition and development of a high-quality portfolio of uranium properties. Magnum's corporate strategy is to acquire advanced-stage uranium properties that are either past producers, have been the subject of prior work programs and/or contain historic resources. Additionally, Magnum will acquire selective early-stage properties should they possess significant geologic merit. Magnum has a proven track record of acquiring projects that meet these criteria as evidenced by its present portfolio. Company's geographic focus is the Western United States, where it have acquired uranium properties in Idaho, Utah, Wyoming, New Mexico, and Canada's Athabasca Basin. The company was founded in 1984 and is headquartered in Vancouver, Canada. | Other Metals/Minerals | Chief Operating Officer | |
BC Advantage Funds Ltd.
 BC Advantage Funds Ltd. Investment ManagersFinance Founded 2003, BC Advantage Funds (VCC) Ltd is a venture capital firm, headquartered in Canada. | Investment Managers | Director/Board Member | |
| TRILLIUM THERAPEUTICS | Biotechnology | Director/Board Member | |
| DBA TELECOMMUNICATION (ASIA)HOLDINGS LTD | Computer Peripherals | Chief Operating Officer | |
| TERRA FIRMA CAPITAL CORPORATION | Finance/Rental/Leasing | Chairman | |
| The Trustees of Columbia University in The City of New York | College/University | Graduate Degree | |
| University of British Columbia | College/University | Undergraduate Degree | |
| University of Toronto | College/University | Undergraduate Degree Corporate Officer/Principal | |
| INOVIO PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| MDS Ventures Pacific, Inc. | Corporate Officer/Principal | ||
Knight's Bridge Capital Partners, Inc.
 Knight's Bridge Capital Partners, Inc. Investment ManagersFinance Knight's Bridge Capital Partners, Inc (Knight's Bridge Capital), a subsidiary of Counsel Corp. (Toronto: CXS.TO), is a family office and private equity firm headquartered in Toronto, Canada with an additional offices in Phoenix, Arizona founded by Kenneth J Finkelstein in November, 2006. | Investment Managers | Chairman | |
Canadian Urologic Oncology Group
 Canadian Urologic Oncology Group BiotechnologyHealth Technology Canadian Urologic Oncology Group operates as a clinical research investigator network. The company is headquartered in Vancouver, Canada. | Biotechnology | Director/Board Member | |
| Princess Margaret Hospital | Corporate Officer/Principal | ||
| HERITAGE GLOBAL INC. | Investment Banks/Brokers | Chairman | |
| ESSA PHARMA INC. | Pharmaceuticals: Major | Chief Executive Officer | |
| Richard Ivey School of Business | College/University | Masters Business Admin | |
| Jewish National Fund of Canada | Corporate Officer/Principal | ||
XORTX Pharma Corp.
 XORTX Pharma Corp. Pharmaceuticals: MajorHealth Technology XORTX Pharma Corp. engages in the discovery, development, and commercialization of therapies for rare diseases. It develops cardio-vascular medications for the treatment of rare diseases such as autosomal dominant polycystic kidney disease, hereditary hypouricemia, cystic fibrosis as well as large market diseases such as hypertension, metabolic syndrome, diabetes, and diabetic nephropathy. The company was founded in 2012 and is headquartered in Calgary, Canada. | Pharmaceuticals: Major | Director/Board Member | |
RFA Bank of Canada
 RFA Bank of Canada Finance/Rental/LeasingFinance RFA Bank of Canada offers residential mortgage solutions. The private company is based in Toronto, Canada. Duncan Hannay has been the CEO of the Canadian company since 2017. | Finance/Rental/Leasing | Chairman | |
POINT Biopharma Corp.
 POINT Biopharma Corp. Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma Corp. is a Canadian company that develops next-generation radiopharmaceuticals for the treatment of cancer. The company is based in Toronto, Canada. POINT Biopharma develops radioligands, which are microscopic, cancer-seeking missiles used to diagnose and treat cancers such as non-Hodgkin's lymphoma and neuroendocrine tumors (NETs). To learn more about the company, interested parties can register online at https\://hub.pointbiopharma.com/investor-day-june-2023. The company was founded by Joe McCann. Joe McCann has been the CEO since incorporation. | Miscellaneous Commercial Services | Chairman Chief Tech/Sci/R&D Officer Director/Board Member | |
| POIT BIOP | Pharmaceuticals: Major | Chairman Founder | |
POINT Biopharma, Inc. (United States)
 POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | Miscellaneous Commercial Services | Chairman Chief Tech/Sci/R&D Officer Director/Board Member | |
| Anglian Holdings LLC | Director/Board Member |
Statistieken
Internationaal
| Canada | 23 |
| Verenigde Staten | 11 |
| Hongkong | 3 |
Sectoraal
| Health Technology | 11 |
| Finance | 7 |
| Consumer Services | 5 |
| Commercial Services | 4 |
| Communications | 2 |
Operationeel
| Director/Board Member | 19 |
| Chairman | 14 |
| President | 6 |
| Corporate Officer/Principal | 5 |
| Chief Executive Officer | 4 |
Sterkste connecties
| Insiders | |
|---|---|
| Robert W. Rieder | 16 |
| Allan Silber | 15 |
| Neil Fleshner | 10 |
| Howard M. Glase | 3 |
- Beurs
- Insiders
- Jay Silber
- Bedrijfsconnecties
